MX2020003460A - Modulacion de la respuesta inmunitaria usando conjugados de anticuerpo-farmaco. - Google Patents

Modulacion de la respuesta inmunitaria usando conjugados de anticuerpo-farmaco.

Info

Publication number
MX2020003460A
MX2020003460A MX2020003460A MX2020003460A MX2020003460A MX 2020003460 A MX2020003460 A MX 2020003460A MX 2020003460 A MX2020003460 A MX 2020003460A MX 2020003460 A MX2020003460 A MX 2020003460A MX 2020003460 A MX2020003460 A MX 2020003460A
Authority
MX
Mexico
Prior art keywords
antibody
immune response
modulating
drug conjugates
cells
Prior art date
Application number
MX2020003460A
Other languages
English (en)
Inventor
Shyra Gardai
Ryan Heiser
David Taft
Carol Anne Ogden
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MX2020003460A publication Critical patent/MX2020003460A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona métodos y composiciones para modular la respuesta inmunitaria en un sujeto, tal como disminuyendo la actividad de las células T reguladoras CD30+ y aumentando la proporción de células T CD8+ a células T reguladoras CD30+, a través de la administración de conjugados de anticuerpo-fármaco que se unen a CD30. La invención también proporciona artículos de manufactura o kits que comprenden estos conjugados de anticuerpo-fármaco que se unen a CD30 para modular la respuesta inmunitaria.
MX2020003460A 2017-10-13 2018-10-11 Modulacion de la respuesta inmunitaria usando conjugados de anticuerpo-farmaco. MX2020003460A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762572345P 2017-10-13 2017-10-13
US201762576017P 2017-10-23 2017-10-23
US201862657511P 2018-04-13 2018-04-13
PCT/US2018/055388 WO2019075188A1 (en) 2017-10-13 2018-10-11 MODULATION OF IMMUNE RESPONSE USING CONJUGATES ANTIBODY-MEDICINE

Publications (1)

Publication Number Publication Date
MX2020003460A true MX2020003460A (es) 2020-08-03

Family

ID=66101160

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003460A MX2020003460A (es) 2017-10-13 2018-10-11 Modulacion de la respuesta inmunitaria usando conjugados de anticuerpo-farmaco.

Country Status (14)

Country Link
US (2) US20200239585A1 (es)
EP (1) EP3694544A4 (es)
JP (2) JP2020536932A (es)
KR (1) KR20200070317A (es)
CN (2) CN118356508A (es)
AU (1) AU2018348198A1 (es)
BR (1) BR112020007119A2 (es)
CA (1) CA3077729A1 (es)
IL (1) IL273720A (es)
MA (1) MA50369A (es)
MX (1) MX2020003460A (es)
SG (1) SG11202002697WA (es)
TW (1) TW201934142A (es)
WO (1) WO2019075188A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL292685A (en) * 2019-11-04 2022-07-01 Seagen Inc Anti-cd30 drug-antibody conjugates and their use in the treatment of HIV infection
KR102685068B1 (ko) * 2020-03-16 2024-07-16 가부시키가이샤 만다무 T 세포성 림프종의 지표의 검출 방법, 및 그 이용
AU2021273256A1 (en) * 2020-05-13 2022-12-15 Seagen Inc. Methods of treating cancer using a combination of anti-CD30 antibody-drug conjugates
CN116940387A (zh) * 2020-12-03 2023-10-24 思进股份有限公司 使用抗cd30抗体-药物缀合物调节免疫反应
KR20230158005A (ko) 2021-03-18 2023-11-17 씨젠 인크. 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출
CA3226977A1 (en) * 2021-08-25 2023-03-02 R.P. Scherer Technologies, Llc Antibodies having humanized framework regions
KR20240099363A (ko) 2021-10-29 2024-06-28 씨젠 인크. 항-pd-1 항체와 항-cd30 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법
WO2023160982A1 (en) * 2022-02-28 2023-08-31 Adc Therapeutics Sa Dosage regimen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511627A (ja) * 2001-11-20 2005-04-28 シアトル ジェネティクス，インコーポレーテッド 抗ｃｄ３０抗体を使用する免疫学的疾患の治療
US8257706B2 (en) * 2006-08-25 2012-09-04 Seattle Genetics, Inc. CD30 binding agents and uses thereof
KR101641345B1 (ko) * 2007-10-12 2016-07-20 시애틀 지네틱스, 인크. 항체-약물 접합체를 이용한 병용 요법
EP3545969B1 (en) * 2009-01-09 2023-12-13 Seagen Inc. Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
WO2015037000A1 (en) * 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
KR20230119265A (ko) * 2016-06-02 2023-08-16 브리스톨-마이어스 스큅 컴퍼니 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1항체의 용도
WO2018112033A1 (en) * 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs

Also Published As

Publication number Publication date
AU2018348198A1 (en) 2020-04-23
CN111683677A (zh) 2020-09-18
IL273720A (en) 2020-05-31
EP3694544A4 (en) 2021-08-11
US20230279133A1 (en) 2023-09-07
KR20200070317A (ko) 2020-06-17
CA3077729A1 (en) 2019-04-18
EP3694544A1 (en) 2020-08-19
US20200239585A1 (en) 2020-07-30
MA50369A (fr) 2020-08-19
JP2020536932A (ja) 2020-12-17
TW201934142A (zh) 2019-09-01
WO2019075188A1 (en) 2019-04-18
BR112020007119A2 (pt) 2020-09-29
JP2024016220A (ja) 2024-02-06
SG11202002697WA (en) 2020-04-29
CN118356508A (zh) 2024-07-19

Similar Documents

Publication Publication Date Title
MX2020003460A (es) Modulacion de la respuesta inmunitaria usando conjugados de anticuerpo-farmaco.
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
CO2021003036A2 (es) Compuestos de anillo fusionado
CO2021005987A2 (es) Compuestos de anillo fusionado
CO2019012080A2 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
CO2018003477A2 (es) Anticuerpos anti-pd1 y métodos de uso
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2019001292A1 (es) Nuevos derivados de quinolina.
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
CO2017004782A2 (es) Conjugados de anticuerpo- farmaco
CL2020000301A1 (es) Nuevos derivados de quinolina.
CO2018003452A2 (es) Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
BR112017008945A2 (pt) Anticorpos anti-cs1 e conjugados fármaco- anticorpo
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
CL2018003527A1 (es) Conjugados de anticuerpo anti-egfr y fármaco.
CO2019009787A2 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
BR112016012146A8 (pt) derivados de aminopiridina como inibidores de quinase da família tam
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
CO2020012524A2 (es) Anticuerpos
BR112016020871A2 (pt) anticorpos anti-mcam e métodos associados de uso
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
EA202090732A1 (ru) Составы для трансдермального введения
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
BR112018009004A2 (pt) conjugados anti-cd3-folato e seus usos